Neoplasms Clinical Trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 188 clinical trials
Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with REGN2810 in Subjects with Newly-Diagnosed Glioblastoma (GBM)
Cemiplimab is a monoclonal antibody (protein) designed to attach to a protein called PD1. PD-1 appears on tumor cells and tumor-infiltrating immune cells, and can be used by the tumor to 'hide' from your immune system. By blocking PD-1, cemiplimab may help your immune system to attack the cancer.
- 0 views
- 19 Feb, 2024
- 1 location
A Study to Evaluate the Safety and Efficacy of Image Guided Surgery using Indocyanine Green for Intramolecular Imaging of Solid Tumors Compared to Standard of Care (TumorGlow) (PRIME)
Indocyanine Green (ICG) is an FDA approved, water-soluble tricarbocyanine dye routinely used in clinical settings for measuring cardiac output, liver function, and retinal angiography and has been in use for over 50 years. Patient diagnosed with solid tumor cancers have a high rate of recurrence when surgery is a treatment. …
- 0 views
- 19 Feb, 2024
- 1 location
The Cancer of the Pancreas Screening-5
The specific Aims of CAPS5 will be: Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls. Aim #2: To compare the prevalence of pancreatic fluid mutations and …
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer
Eligible subjects will have lung cancer that has a mutation in a key cancer gene called KRAS, and the cancer has spread to other parts of their body.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 35217: A Phase 1B/2 Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
- 0 views
- 19 Feb, 2024
- 1 location
UPCC 03920: A Phase 1/1b Open-label Dose-escalation and Dose-expansion Study of TPST-1120 as a Single Agent or in Combination with Systemic Anti-Cancer Therapies in Subjects with Advanced Solid Tumors
Subjects may receive TPST-1120 alone or in combination with nivolumab. Subjects eligible to participate are those with advanced solid tumors.
- 0 views
- 19 Feb, 2024
- 1 location
A Phase 1 Study of the Highly-selective RET
This is a phase 1 study with Highly-selective RET inhibiter, Blu-667, in patients with Thyroid Cancer, Non-Small cell lung cancer and other advanced solid tumors. The study will be conducted at multiple centers in the United States and Europe.
- 0 views
- 19 Feb, 2024
- 1 location
Early diagnosis of transthyretin cardiac amyloidosis
We would like to establish non-invasive methods using cardiac MRI and radionuclide imaging techniques (pyrophosphate technetium scan (PYP) to detect early stage CA infiltration in the heart.
- 0 views
- 19 Feb, 2024
- 1 location
Genomic Epigenetic Proteomic Metabolomic and Immunologic Characterization of Metastatic Neuroendocrine Tumors Surviving Transarterial Embolotherapy
mNET is commonly treated with TACE or TACE. mNET cells can survive TACE or TARE ischemic conditions. In this study, we will biopsy mNETs being treated with TACE or TARE prior to treatment, after treatment, and again at recurrence to characterize the metabolic, immunologic, and genetic profile of the cells …
- 0 views
- 19 Feb, 2024
- 1 location